|New York Law Journal|
|VOLUME 249—NO. 77
||TUESDAY, April 23, 2013
A Tale of How Successfully Raising
Capital Leads to Bankruptcy
Market research that actually gets to the point!
Neogenix Oncology was
organized in 2004 when Dr. Ariel Hollinswhead, professor
of medicine and head of the
George Washington University
Cancer Research Laboratory, assigned
her research on developing therapeutic
and diagnostic products to treat
pancreatic, colon, lung, prostate and
colorectal cancers to the company.
Its efforts focused primarily on the
development of therapeutic monoclonal
antibodies targeted against pancreatic
and colorectal cancer. To fund itself
through the start-up and developmental
stages it relied on the sale of its common
stock to third parties. And this is where
our tale of woe begins.1
Between 2004 and 2011 Neogenix
raised $47.1 million through the sale
of shares using third-party finders
who were not registered to sell stock
either with the Securities and Exchange
Commission or any state securities
commission. These finders made a
total of 83 placements and were paid
But all of this had to surface. The
Securities Exchange Act at the time
required companies with over $10 million
in assets and over 500 shareholders of
record to register with the SEC and file
quarterly and annual reports.
Neogenix registered its stock with
the SEC in April 2006. In its filings with
the SEC, Neogenix disclosed these
numerous sales of its common stock
The JOBS Act doesn't really
help the small companies
seeking capital through private
placements without the use of
In October 2011 the SEC's Philadelphia
Regional Office wrote Neogenix asking
for an explanation of its numerous sales
of stock through the use of finders that
were not SEC-registered broker-dealers.4
Under the Securities Exchange Act it is
illegal to sell a company's common stock
through the use of third parties that are
not registered as broker-dealers with
the SEC. Transactions in violation of the
Securities Exchange Act can be voided
by the party who did not violate the
act. In addition, many state securities
laws or "blue sky" laws provide a right
of rescission to the buyer of securities
sold by a finder that is not licensed
under that state's securities laws.
Neogenix may have had an inkling of
this because in May 2011 it terminated
its chief financial officer.
This letter from the SEC caused great
consternation at the company and
with its accountants. How should they
account for the possible liability since
these various sales of common stock
using finders could be rescinded? It took
Neogenix and its accountants some six
months to resolve this.5 Neogenix got the
SEC's Chief Accountant's Office to agree
that until suits were filed for rescission
of these sales, it would disclose the sales
in possible violation of the law as a
footnote to its financial statement and
estimate its contingent liability. In the
footnotes to its Dec. 31, 2011, financial
statements, Neogenix stated that no
suits had been filed and estimated its
contingent liability could be as much
as $31 million. These same financial
statements showed the company had
total assets of $6,341,626 and a net worth
of $4 million.
With these disclosures their sources
of capital dried up. They retained an
investment banking firm in mid-2011 to
raise capital. But with no success. They
retained another investment banking
firm in 2012 to advise them what to
do—merge, sell to another company or
reorganize under the Bankruptcy Code.6
Reorganizing under the Bankruptcy
Code would allow the successor to
Neogenix to take over the research
that had been performed but without
assuming any liability for the sales of
shares using unregistered finders.7
The end result was that Neogenix
filed under Chapter 11 of the
Bankruptcy Code, and sold itself to a
company organized by several of its
insiders. As a result of the bankruptcy
process, the contingent liability of
Neogenix from the sale of its stock
using unlicensed finders was wiped
out and was not assumed by the buyer
of its assets. Part of this sale included
a distribution of the buyer's stock to
the then shareholders of Neogenix, but
nowhere near the number of shares that
these shareholders held in Neogenix.
And to rub salt in their wounds, the
buyer offered to sell its shares to the
existing Neogenix shareholders.8
The JOBS Act Doesn't Help
The Jumpstart Our Business Startups
Act (JOBS Act) passed in 2012 makes
several changes to the securities laws
that on their face appear to make the
capital-raising process easier for startup
companies. But it doesn't really help
the small companies seeking capital
through private placements without
the use of SEC-registered broker-dealers.
First, it provides an exemption from the
requirement to register with the SEC as
a broker-dealer for companies/finders
that make or arrange private placements
under SEC Rule 506 (sales to accredited
investors, no general solicitations).
However, that exemption is only from SEC
and not state broker-dealer registration
requirements, and the exemption is
only available if the broker/finder
does not receive any transaction-based
compensation,e.g., based on sale of such
The JOBS Act provides for
crowdfunding. But the
crowdfunding must be through
an entity that is either registered
with the SEC as a broker-dealer
or crowdfunding portal and is
also a member of FINRA.
Second, the JOBS Act provides for
crowdfunding. But the crowdfunding
must be through an entity that is
either registered with the SEC as
a broker-dealer or crowdfunding
portal and is also a member of
the Financial Industry Regulatory
Authority (FINRA). Neither the SEC
nor FINRA have yet adopted, much
less proposed, any rules regarding this
registration process and the related
rules governing the activities of such
crowdfunding portals. In October
2012, the SEC in its publication of its
rule-making agenda provided no time
frame for the issuance of or proposal
of such rules.
Further, the JOBS Act prohibits
the crowdfunding portal from
compensating any promoter, finder or
lead generators for providing it with
information about potential investors,
and amended the Securities Exchange
Act to provide in the definition of a
crowdfunding portal that it could not
compensate employees, agents or
others for soliciting or based on the sale
of securities displayed or referenced
on the crowdfunding portal's website.
Dilemmas for Start-Ups
What does all this mean for the startup
and development stage company that
badly needs capital? If you succeed,
sooner or later you will have to either
register your stock with the SEC, or have
an audited financial statement and an
opinion from counsel to get a major
bank loan, when you sell out to a public
company or go public yourself. As part
of that process the sale of stock using
unlicensed finders will be discovered,
and will be reflected in a lower price
or, worse yet, the bank, buyer or
underwriter walking away from the
Neogenix is a perfect example of the
decisions and dilemmas faced by every
start-up company that is going to raise
money and perhaps go public. (Other
dilemmas include the decision to do
PR and market or not and when, and
included in that is what information to
release to the public and analysts, and
whether or not to listen to the Board
of Advisors and/or Directors when
their recommendations are dissimilar
or outright contradictory to the path
management wants to pursue). All along
the way, advisors warned of problems
but no one in the company listened, or
merely brushed them off. Rational minds
might have been overruled by others.
The internal pressures to reach
a liquidity milestone or event are
enormous. The temptations to pursue
shortcuts, legal, quasi-legal, and not
legal at all are often overwhelming. In the
race to reach these goals, shareholders,
both internal and external, as well as
the ultimate good of the company over
the long run are often overlooked.
Add in the arrogance of management,
particularly scientist-founders, and the
ingredients for a recipe guaranteed to
cause indigestion (at the very least)
after the meal are complete.
In the current funding environment
there is a lot of negativity expressed toward venture capitalists and the
amount of control they want for their
investment. However, in this example,
had VCs been involved, the entire
situation would have been avoided. Yes,
certainly, there would have been other
big issues. But the company would be
further down the road toward proof-ofconcept
and product or platform than
they are today. Today, in-fighting over
money and power takes precedence
over the development of the company.
Soon responsibility for decisions may
be added to the mix if jail time or other
substantial penalties become imminent.
Everyday start-up companies are
given good advice from internal or
outside sources. It is up to them to
choose the right road from the start.
The question they must ask when they
are desperate for money is, do I gamble
and take a risk (always defined by the
company as a shortcut) or do I do the
right thing and delay gratification. The
answer is often the key to the company's
1. Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the fiscal year ended Dec. 31,
2011, of Neogenix Oncology Inc. as filed on July 7, 2012 (2011
Form 10-K); Notification of Late Filing, Form 12b-25 for the period
ended Sept. 30, 2011, filed by Neogenix Oncology Inc. Neogenix
Oncology Inc. letter to shareholders dated June 29, 2012
2. Neogenix Oncology Inc. 2011 Form 10-K.
In 2004 after it originally issued its common stock to its
founders, Neogenix made eight placements of stock totaling
958,000 shares. Four of these placements, totaling 521,000
shares for $521,000, were made through persons and entities
that were not registered with the SEC or any state securities
commission. In 2005 Neogenix sold 1,526,123 shares in
10 placements. Seven of these placements, totaling 941,123
shares and raising $1,172,248 were made using "finders."
In 2006 it sold 481,966 shares in 13 placements. It made seven
of these placements totaling 284,133 shares using finders
and raised $822,399. In 2007 Neogenix sold 2,234,695 shares in
15 placements. It used finders in 10 placements. The finders
sold 2,135,483 shares raising $7,195,670. In 2008 Neogenix sold
4,633,975 shares in 18 placements. It used finders in 12 placements
to sell 2,139,725 shares raising $2,253,750.
In 2009 it sold 1,949,183 shares in 13 placements. It used
finders to make 12 placements totaling 3,196,058 shares and
raised $10,103,265. In 2010 Neogenix sold 884,398 shares in
10 placements. It used finders to make all these placements
raising $10,253,725. In 2011 Neogenix made four placements. It
used finders to make three placements totaling 228,101 shares
3. Form 10 as filed by Neogenix Oncology Inc. with the Securities
and Exchange commission on April 30, 2010.
4. Neogenix Oncology Inc. 2011 Form 10-K.
5. Neogenix Oncology Inc. July 6, 2012, letter to shareholders,
Neogenix Oncology Inc. 2011 Form 10-K.
6. Neogenix Oncology Inc. 2011 Form 10-K.
7. Neogenix Oncology Inc. letter to shareholders of June 29,
8. Neogenix Oncology Inc. Current Report on Form 8-K for
Sept. 20, 2012.
Morris N. Simkin is a partner at McLaughlin & Stern.
Sandra Holtzman is president and founder of Holtzman
Communications, a marketing firm specializing in the
life sciences. David Schmidt is a principal at Advanced
Materials Advisory, a marketing and business development
consulting company in Chester, N.J., that helps growing
advanced technology companies.
For further information, please view my recent
Sandra Holtzman will be on a panel dealing with the 'Nuts and Bolts of setting up In New York'
Monday, November 16,
Is the 2009 UK Trade & Investment's (UKTI) Digital Mission: Hosting 25 UK IT companies at the British Consulate in NY. Sandra Holtzman will be on a panel dealing with the 'Nuts and Bolts of setting up In New York'
For further information, please visit www.uktradeinvest.gov.uk
Sandra Holtzman is a Founder and Partner in new consultancy EHR Empowerment Consortium www.ehrempowerment.com.
Sandra Holtzman is a Founder and Partner in new consultancy EHR Empowerment Consortium www.ehrempowerment.com.
Sandra Holtzman is co-founder and partner in a new consultancy formed to help healthcare providers qualify for government stimulus monies through the American Recovery and Reinvestment Act - ARRA.
The organization is called EHR Empowerment Consortium (EHREC) and her partner and co-founder is Todd Frech. Together, through EMREC, they are able to offer clients a combined 50 years of background in healthcare information technology.
The EHR Empowerment Consortium will work with physicians and other healthcare providers (including chiropractors, midwives, DOs, etc.) and their practices to qualify for stimulus funds. As consultants, it will be Sandra and Todd’s job to create and oversee a smooth process for qualifying for these funds and the vetting and contracting of electronic medical record vendors.
Along with their teams Sandra and Todd will serve as the CIO for individual and small practices who may barely know they are eligible for funding and who usually don't have the time and expertise required to navigate the world of ARRA (American Recovery and Reinvestment Act) compliance. That means they will handle all the details that go with "meaningful use" and other compliance programs and performing due diligence with EMR vendors.
The EHR Empowerment Consortium has offices in New York City and Ravenel, South Carolina.
Both Sandra and Todd continue to provide services with their existing companies, Holtzman Communications, LLC and Ocius Medical Informatics, LLC respectively.
For more information, please contact Sandra at firstname.lastname@example.org
Sandra Holtzman discusses “Don’t Be A Marketing Horror Show” at NJ Entrepreneurs Forum
NJEF's October 8th program features Sandra Holtzman, warning you to "Don't Be A Marketing Horror Story". Sandra literally wrote the book on the subject of marketing for early stage tech companies, and it's entitled "Ten Lies Startups Tell Themselves to Avoid Marketing". It's a great read and well worth your time. But come on Thursday October 8th from 4-6 p.m., and you'll gain so much more: inside information and the do's and don'ts of technology company marketing, the opportunity to meet your peers and learn what your competitors are doing.
See you on the 8th. Register now at www.njef.org.
Sandra Holtzman spoke at the Genetic Engineering News annual sales conference.
She spoke on “Economics, Amoebas, and Imitators”.
Cornell University’s Startup Boot Camp features Sandra Holtzman on panel:
The Frontlines: Making the Pitch on June 4, 2009.
Holtzman Communications is on AdAge.com's Top U.S. Agencies
May 20, 2009
Holtzman Communications is on AdAge.com's Top U.S. Agencies from All Disciplines List
Every year AdAge.com does an annual comprehensive listing of over 900 of the top ad agencies in the US. Holtzman Communications, LLC, a micro boutique agency that is independently held, moved up three positions from last year's standings.
Sandra Holtzman, the President and owner of the agency, says that a significant contributor to the firm's continuing success, "is our ability to provide services and strategic thinking that increases our clients' exposure, brand, and ROI. It's important in any marketplace, but particularly critical in today's tough economic environment. We make every marketing dollar work harder than ever before."
She further states that one way the company does this is through their proprietary customer-focused qualitative market research methodology called OpenMind Research. Says Holtzman, "It's a highly cost-effective way for our customers to reach their market by helping their audience(s) reach them. After an OpenMind session, our clients have accurate and highly targeted marketing messaging that can be used in any medium."
Holtzman Communications is an award-winning advertising, marketing, interactive, branding, corporate and product image and positioning, and PR agency that specializes in all aspects of life sciences, Pharma, healthcare IT, IT, green/clean, consumer, B-to-B, and B-to-C spaces, from small start-ups to Fortune 500 companies. Sandra Holtzman, creative director and copywriter, founded the agency in 1997 after 15 years of success on Madison Avenue working with such clients as Merck, Warner-Lambert, Colgate, Johnson & Johnson, Acura car, Pfizer, Chesebrough-Ponds, New York Wine and Grape Counsel, Foot Joy golf shoes and gloves, Bury-Lu cookies, among others. The team consists of creative director-level art directors and copywriters, CIO-level programmers, information architects, media planners, account managers, market researchers, strategic and management consultants, among others.
The Morning X Live internet radio show featured Sandra Holtzman on April 8.
She discussed key marketing strategies that start up companies need in order to succeed.
What’s your value proposition and why is it important to your product/company?
Join our interactive panel as they build "value propositions" from real patent abstracts. With audience participation, the panel will determine real-life applications from some of the newest patents; (if you have a start up company, division or new product and would like us to work on your value proposition, please bring it in) identify potential benefits of those products and services, and create "90 second elevator pitches." With your help, we will separate features from benefits, address questions such as: what are the benefits of this new patented product or service, what is the best business model to use, and what support do you need to market or license it. Get key advice on the significance of branding, logos, and marketing, how to get the proposal past Legal - what information do you need so Legal understands what you want to get done, how to garner one's facts so Legal is more inclined to give the go-ahead, etc.
P.S. - This is an essential business development task for professional service firms!
Neil Schaffer has served in executive management roles across a number of industries. Mr. Schaffer was the founder and since 2005 has served as CEO of Longview Consulting Group, a strategic advisory firm working with growing small and middle market businesses in the areas of marketing and financing strategy. Previously, he has led corporate operations, finance and administration while serving as EVP and CFO of two innovative technology companies in the advertising and media business – AudioAudit, Inc. (sold to Nielsen Media Research in 2005) and MediaPort, a technology consortium sponsored by Omnicom, Interpublic, and WPP Group.
Along with several former senior executives from Citicorp and three Ivy League computer science professors, he co-founded iPrivacy LLC, a software and services company focused on Internet privacy and security. Mr. Schaffer previously served as CFO of several industrial, distribution, and technology companies, including Horizon Paper Company, a leading paper brokerage firm; The Carson Group, Inc., a stock surveillance and financial information services company (sold to Thomson Financial); and The Hain Celestial Group (NASDAQ: HAIN), now the largest natural-products manufacturing company in the U.S.
Mr. Schaffer began his career as a certified public accountant with the middle-market practice group of Price Waterhouse in New York. He is a graduate of Binghamton University.
Sandra Holtzman is an award winning writer and strategist who founded Holtzman Communications, LLC in 1997. She has over 20 years of expertise in virtually every area of pharmaceutical advertising (ethical, OTC, DTC), nanotech, biotech, and chemical as well as emerging and converging technologies. She also has experience in business-to-business and consumer advertising.
In addition to being a co-chair of the NY Chapter of LES, Sandy has authored "Lies Startups Tell Themselves to Avoid Marketing" and lectures in the US and around the world on all aspects of strategic marketing including intellectual property, global, web development, and market research. Her company has development a proprietary methodology for customer-focused market research that helps companies communicate their value propositions fast and efficiently in today’s fast-paced marketing environment. She also writes for several journals on marketing and science subjects.
DATE & TIME:
Thursday, October 2, 2008
5:15 to 7:30 PM
5:15 pm: Networking session
6:00 pm: Panel discussion with Q&A
7:00 pm: Networking
Frankfurt Kurnit Klein & Selz PC
10th Floor Boardroom
488 Madison Avenue (between 51st and 52nd)
New York, NY 10022
LES Member: $50.00 by Sep 30, $55.00 at the door
Non-member: $60.00 by Sep 30, $65.00 at the door
Click HERE to register with interactive PDF form
For questions regarding registration please contact:
LES Membership & Chapter Coordinator
For questions about the event contact:
LES Chapter Chair
DIRECTIONS to Frankfurt Kurnit Klein & Selz PC 488 Madison Avenue (between 51st and 52nd)
Frankfurt Kurnit Klein & Selz' 10th Floor Boardroom is readily accessible by mass transit. You can easily walk from Grand Central Station at 42nd St. Or - You may take the #6 local IRT Lexington Avenue train to 51st Street and the E and V trains to the Lexington Avenue stop and walk about 3 blocks west.
Master Class 101 -- Doing Web 2.0 Business in the US – A roundtable sponsored by the British Consulate and UK Trade and Investment
On Monday, September 15, Sandra Holtzman will be at the roundtable with Heard Magazine, IBM, The Hatchery, Mayors Office -- International Division and Empire State Development Corporation. She represents Holtzman Communications and will discuss the following topics:
- New ways to do market research that will give your company a competitive edge
- How to market yourself in a saturated and competitive environment
- Leveraging her expertise based on her book, LIES STARTUPS TELL THEMESELVES TO AVOID MARKETING
- Hints about branding/marketing your company in the US
Sandra Holtzman spoke about international marketing of life sciences at Shanghai Bio-forum conference
Sandra Holtzman spoke about international marketing of life sciences at the 13th Chinese Biopharmaceutical Association Conference and the 10th Shanghai International Forum on Biotechnology and Pharmaceutical Industry in Shanghai.
The FENG New York, NY Chapter
5:30 PM to 8:30 PM
Lee Hecht Harrison
200 Park Avenue (MetLife Building), 26th Floor
“Financial and Marketing Strategies for Start-Ups and Entrepreneurs”
Starting your own company as an entrepreneur requires considerable financial, marketing, and technical expertise. Many start-ups fail because their core competencies are too narrow; a novel idea or product alone does not spell success. In particular, many have difficultly raising sufficient capital to launch the initiative, or skimp on marketing under the false assumption that their novel concept will sell itself. Consequently, firms with considerable potential are often forced to close their doors not as a result of a flawed invention, but as a result of inadequate or faulty launch strategies.
The FENG New York has invited two experts in the start-up, entrepreneur, and angel investor fields to provide their insights into the various components of successful launch strategies. Doors open at 5:30, with speaker presentations beginning at 6:00. Both speakers will have the floor for up to 30 minutes, followed by a half hour of group Q&A. The networking hour begins at 7:30 and goes to 8:30. In order of speaking:
Michael Segal is the General Partner of Joshua Capital Partners, a private investment partnership. He is also founder of the boutique investment banking firm M.J. Segal Associates, which he created in 1987. M.J. Segal was formed to address the many problems faced by emerging/growth companies in accessing capital markets. In particular, these companies are often unable to raise capital through the large Wall Street firms. His firm actively focuses on developing relationships with institutional investors to find alternative sources of equity and debt capital for its clients, as well as create corporate strategies. His primary criticism of the investment process is that it tends to be unnecessarily complicated and tedious; thus his firm concentrates on developing realistic business plans and incubation time frames for its clients as they launch their initiatives. Michael is a member of the screening committee for the Tri-State Private Investors Network, one of the area’s leading Angel groups; and is a Founder of New York Private Equity Forums.
Sandra Holtzman founded Holtzman Communications, LLC in 1997. She is a marketing expert in the pharmaceutical industry, with expertise in several sectors including biotech, nanotech, chemical, and emerging and converging technologies. Her experience in this sector led her to co-author a recent book on marketing mistakes of emerging companies, entitled “Lies Start-Ups Tell Themselves to Avoid Marketing.” The book covers a wide range of managerial misconceptions and tactical errors that typically lead to the demise of entrepreneurial firms. Sandra will discuss the main points of the book, which will be on sale at the event. She also authored the marketing chapter of “A Comprehensive Guide to Business Incubation,” a top-selling book published by the National Business Incubation Association. Further, Sandra contributes as a columnist on a regular basis to the trade periodicals “Oncology Business Review” and “Lab to Wall Street.”
In order to attend this event please reply promptly to The FENG New York at email@example.com, providing your name, preferred email address, and primary telephone number. After the meeting, this contact information will be circulated for networking purposes. A $20 cover charge for chapter administration is payable at the door. If your plans change and you are unable to attend, please provide notification so that another member can have your seat. As a matter of courtesy to the speakers, please turn off cell phones and do not leave the meeting until its conclusion.
The dress code is business casual.
From 45th Street entrance walk up one flight to 2nd floor check-in.
From 42nd Street entrance walk through Grand Central Terminal, take escalators up two flights to 2nd Floor reception.
Navigating the startup road-- Thursday, October 11, at NJEF's Entrepreneur University
sponsored by the NJ Entreprenurial Forum
Why is a business plan not enough without a marketing plan?
How do you identify the early adopters who will purchase your product?
These and other questions will be answered on October 11, 2007, from
4-6 p.m., at the CCIT when NJEF's Entrepreneur University hosts Sandra
Holtzman at a special session of the
Entrepreneurs Forum. Sandra will present the findings of her book, "Lies
Start-ups Tell Themselves to Avoid Marketing" at the Commercialization
Center for Innovative Technologies, at 675 Route 1 South, North Brunswick,
NJ. Register in advance for $30 ($35 at the door) at the NJEF website,
www.njef.org . Come for the good food and camraderie,
stay for the networking and knowledge.
Sandra Holtzman will be giving a marketing seminar at University of Rochester School of Medicine December 4, 2007
Rochester Clinical & Translational Research Curriculum
December 4, 2007
The Truth About Marketing a Startup Business
Sandra Holtzman recently spoke at the Rochester Chapter of the Licensing Executives Society.
"Lies Startups Tell Themselves to Avoid Marketing"
President, Holtzman Communications, LLC
Lead Co-Chair, New York City Chapter of Licensing Executive Society
Lite luncheon will be served. Please join us!
@ 12:15 - 1:15pm
LeChase Assembly (G9576)
LeChase Assembly is in the Arthur Kornberg Medical Research Building, just past the Coffee Shop in the Atrium on the ground floor, then through the double doors.
Panelist at the World Intellectual Property Organization (WIPO) Licensing Training Program: Protection, Marketing and Licensing Research Results
Organized by The World Intellectual Property Organization (WIPO) in cooperation with The University of West Indies (UWI), The Scientific Research Council of Jamaica (SRC), The Jamaica Intellectual Property Office (JIPO), and The Jamaica Promotions Corporation (JAMPRO).
The main objective of this event was to empower technology managers in research institutions and the private sector to value and protect their intellectual property assets, to identify opportunities and risks in licensing agreements, and to negotiate successful technology licensing agreements.
Focus on Canadian Life Sciences and IT Companies
Endorsed by the University of Manitoba's Technology Transfer Office
"Lies That SMEs & StartUps Tell Themselves to Avoid Marketing!" and overcoming barriers for Canadian companies entering the US market were the subjects of Sandra Holtzman's presentation to the Health Care Products Association of Manitoba at The Hotel Fort Garry, Winnipeg, Manitoba. As a result, her company was endorsed by the University of Manitoba's Technology Transfer Office.
Appeared at New Jersey Biomedical Engineering Showcase
Sandra Holtzman will be selling and signing her new book "Lies Startups Tell Themselves to Avoid Marketing" at the 4th Annual New Jersey Biomedical Engineering Showcase at the New Jersey Institute of Technology (NJIT) Campus Center Ballroom (second floor), Newark, New Jersey.
Sponsors include NJIT, Rutgers-The State University of New Jersey, Princeton University, The University of Medicine and Dentistry of New Jersey, Stevens Institute of Technology, Kean University, the Public Health Research Institute of Technology, The Biotechnology Council of New Jersey, The New Jersey Commission on Science and Technology, The New Jersey Commission on Spinal Cord Research, the HealthCare Institute of New Jersey, and the Biomedical Engineering Alliance for Industrial Internships.
This year's theme is Biomedical Engineering Innovation from Concept to Clinic to Commerce. The program includes keynote panels exploring the topics of technology commercialization, New Jersey State support for the Bio/Life Sciences Cluster and global perspectives and success stories on translational research.
Planting New Ideas at BioStrategy Partners First Sightings 2007
Sandra Holtzman will be speaking and signing her new book, "Lies Startups Tell Themselves to Avoid Marketing", at BioStrategy Partners' First Sightings 2007 in Princeton, NJ. "Resources, Challenges, and Opportunities for Emerging Life Sciences Companies" is a mentoring and networking program for pre-seed and seed-stage life sciences companies in New Jersey, Pennsylvania, and Delaware.
First Sightings is a coaching process and networking opportunity for emerging life sciences companies. BioStrategy Partners provides discovery, pre-seed, and seed life sciences companies with the tools to help them grow their businesses to the next level.
Hatching the Right Companies at the NBIA Annual Meeting
Holtzman Communications was a participating sponsor at the National Business Incubation Association's 21st International Conference on Business Incubation in Seattle, Washington. NBIA is the world's leading organization advancing business incubation and entrepreneurship. This meeting provided thousands of professionals with the information, education, advocacy, and networking resources to bring excellence to the process of assisting early-stage companies worldwide.